Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.55 |
| ▸ | RAB9A | P51151 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KHK | P50053 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21493561 | 1.00 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL21493542 | 1.00 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5476430 | 0.94 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL594567 | 0.94 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| Water SCHEMBL22462471 | 0.92 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL994332 | 0.92 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1163023 | 0.88 | MAPK1 (0.59) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1163022 | 0.88 | MAPK1 (0.59) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL28280152 | 0.88 | MAPK1 (0.59) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL161227 | 0.85 | NPC1 (0.72) | NPC1RAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745409-B2 | Azepane inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-18 | — | — | US | disclosed |
| US-20190322685-A1 | AZEPANE INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745409-B2 | Azepane inhibitors of menin-MLL interaction | MEN1, MLLT1, BMI1 | NPC1 3963/4885RAB9A 2916/4885SMN1; SMN2 866/4885 |
| US-20190322685-A1 | AZEPANE INHIBITORS OF MENIN-MLL INTERACTION | MEN1, MLLT1, BMI1 | NPC1 3963/4885RAB9A 2916/4885SMN1; SMN2 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.